ACTengine® IMA203 Combined With mRNA-4203 — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
United States
University of California San Francisco, San Francisco, California Dana Farber Cancer Institute, Boston, Massachusetts Memorial Sloan Kettering Cancer Center, New York, New York MD Anderson Cancer Center, Houston, Texas Last updated January 2026